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Abstract
Adipose tissue (AT) fatty acid (FA) composition partly reﬂects habitual dietary intake. Circulating NEFA are mobilised from AT and might act as
a minimally invasive surrogate marker of AT FA proﬁle. Agreement between twenty-eight FA in AT and plasma NEFA was assessed using
concordance coefﬁcients in 204 male and female participants in a 12-month intervention using supplements to increase the intake of EPA and
DHA. Concordance coefﬁcients generally showed very poor agreement between AT FA and plasma NEFA at baseline SFA: 0·07; MUFA: 0·03;
n-6 PUFA: 0·28; n-3 PUFA: 0·01). Participants were randomly divided into training (70 %) and validation (30 %) data sets, and models to predict
AT and dietary FA were ﬁtted using data from the training set, and their predictive ability was assessed using data from the validation set. AT
n-6 PUFA and SFA were predicted from plasma NEFA with moderate accuracy (mean absolute percentage error n-6 PUFA: 11 % and SFA: 8 %),
but predicted values were unable to distinguish between low, medium and high FA values, with only 25 % of n-6 PUFA and 33 % of SFA
predicted values correctly assigned to the appropriate tertile group. Despite an association between AT and plasma NEFA EPA (P= 0·001) and
DHA (P= 0·01) at baseline, there was no association after the intervention. To conclude, plasma NEFA are not a suitable surrogate for AT FA.
Key words: NEFA: Adipose tissue fatty acids: EHA supplementation: DHA supplementation: Prediction equations: Surrogate
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The fatty acid (FA) composition of adipose tissue (AT) is
considered to reﬂect habitual intake of FA, particularly of n-3
and n-6 PUFA(1), trans-FA(2) and SFA from dairy sources(3).
However, the AT content of some SFA, such as palmitic acid,
does not reﬂect dietary intake well, probably because those FA
are synthesised de novo, as well as coming from the diet(1,4,5).
AT FA composition is also regulated by other factors; for
example, increased physical activity is associated with a higher
proportion of SFA with a correspondingly lower proportion of
MUFA(6), and insulin resistance is associated with an increased
proportion of palmitic acid and a decreased proportion of PUFA
within AT(7). Inﬂammation within AT is implicated in the
development of insulin resistance and other aspects of meta-
bolic syndrome(8,9), and AT inﬂammation is inﬂuenced by FA
availability(10). Therefore, there is much interest in knowing the
FA composition of AT for understanding both dietary intake and
AT biology. However, AT biopsy is an invasive procedure and
is not practical to conduct in large trials, in the ﬁeld or in vul-
nerable populations. In the fasting state, circulating NEFA are
primarily derived from AT lipolysis(1,11), and if the composition
reﬂects that of AT, NEFA may provide a minimally invasive
surrogate marker of AT FA composition. Previous studies have
reported good correlations between FA species in NEFA and
AT, although these studies have been limited to a comparatively
* Corresponding author: C. G. Walker, fax + 44 1223 437 515, email Celia.Walker@mrc-hnr.cam.ac.uk
Abbreviations: AT, adipose tissue; FA, fatty acids.
British Journal of Nutrition (2015), 114, 756–762 doi:10.1017/S0007114515002251
© The Authors 2015. This is an Open Access article, distributed under the terms of the Creative
Commons Attribution licence (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted
re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
small number of participants, to cohorts that are not repre-
sentative of the population or to studying a limited number of
FA(1,5,12). In the current study, we investigate whether FA pro-
ﬁles of NEFA may act as a surrogate for AT in 204 male and
female participants of varying age and BMI. Furthermore, the
proﬁles are investigated before and after a 12-month period of
supplementation with marine n-3 PUFA designed to reﬂect 0–4
portions of oily ﬁsh/week and which was demonstrated to
modify the FA composition of both plasma NEFA and AT(13).
Methods
Data for this analysis were obtained from a two-centre study
examining change in FA proﬁles of nine blood and tissue
fractions in response to 12 months of ﬁsh oil capsule
supplementation equivalent to the amounts of marine n-3 PUFA
provided by 0, 1, 2 and 4 portions of oily ﬁsh/week
(1 portion= 1·5 g EPA and 1·77 g DHA), with placebo capsules
(high oleic acid sunﬂower oil) taken on the remaining days(13).
The study was registered at www.controlled-trials.com as
ISRCTN48398526 and is described in detail elsewhere(13). All
procedures were approved by the Suffolk Local Research Ethics
Committee (approval 05/Q0102/181), and written informed
consent was obtained from all participants. The study participants
were stratiﬁed by age and sex(14), had a BMI range of 18·5–34·9
(median= 25·2) kg/m2 and were all described as healthy. The FA
pools studied included AT and plasma NEFA, both of which
responded in a dose-dependent manner to the EPA and DHA
supplementation, such that at 12 months in NEFA the mean
observed values for combined EPA+DHA were 0·53 (SD 0·07) %
(P< 0·0001) higher per portion (dose), with the 0 portions
mean= 1·46 (SD 0·65). In AT, the values for combined EPA+DHA
were 0·05 (SD 0·01) % (P< 0·0001) higher per portion, with the 0
portions mean= 0·40 (SD 0·21), as previously reported(13).
To monitor background diet, participants completed three
unweighed 4-d diet diaries recording food and drink as esti-
mated portions over 3 weekdays and 1 weekend day at 0, 6 and
12 months of the intervention period. Data were analysed using
an in-house database(15). In addition, during the nine study
visits over the 12-month period, participants were asked to
report any changes in diet, and were asked speciﬁc questions
related to cooking oils and spreads and to any white ﬁsh con-
sumption, and as previously reported there was no difference in
reported dietary FA intake during the 12-month period(13).
Fasting blood samples and an abdominal subcutaneous
AT biopsy were taken at 0, 6 and 12 months during a clinic
visit. Plasma NEFA and AT were analysed for FA composition.
The preparation and analysis of blood and AT samples has
been described previously(13). Brieﬂy, FA were analysed by
GC, performed on a Hewlett Packard 6890 gas chromatograph
(Hewlett Packard) ﬁtted with a BPX-70 column (30m×
0·22mm×0·25 μm; Agilent Technologies). The instrument was
controlled by, and data were collected using, HPChemStation
(Hewlett Packard). FA methyl esters were identiﬁed by comparison
of retention times with those of authentic standards run previously.
To determine whether NEFA may be used as a biomarker for
AT, the agreement between NEFA and AT for individual FA and
FA classes (SFA, MUFA, PUFA, n-3 PUFA and n-6 PUFA) was
assessed using Lin’s concordance correlation coefﬁcients(16) at
the three time points over the 12-month study (0, 6 and
12 months). The relationship between AT and NEFA was also
assessed by Spearman’s rank correlation coefﬁcients at 0, 6 and
12 months. To assess whether NEFA values are a useful surro-
gate for AT, linear regression models were ﬁtted to the baseline
data from a randomly selected sample (70 % of the total cohort,
the training set). The outcome variables were FA class in AT
with NEFA as a predictor variable. In addition, age, sex and BMI
were included as predictor variables where this improved the ﬁt
of the models (assessed using R2 as a measure of explained
variance). These models were then used to predict the FA in AT,
using baseline data from the remaining 30 % of the data set (the
validation set). The differences between the predicted and
observed AT FA values were assessed visually using scatter
plots and by the mean absolute percentage error (MAPE). The
performance of the predicted values was assessed by splitting
the observed and predicted values into tertiles to determine
whether the predicted values could be correctly assigned into
the low-, medium- or high-FA categories.
All analyses were performed with Stata version 13 (StataCorp LP).
Results
Study population
There were 204 participants enrolled into the 12-month study,
and 163 participants completed the 12-month visit. The number
of participants for whom AT samples were available for com-
parison with NEFA at each time point and the characteristics of
those participants are shown in Table 1.
There were no differences in any of the characteristics or the
dietary fat intake of the participants included at each time point.
The baseline participant characteristics for the training and
validation sets used to build and test the prediction models are
shown in Table 2. There were no differences in baseline char-
acteristics between the two sets.
Fatty acid proﬁles in NEFA and adipose tissue in the study
population at baseline
The contributions of SFA and n-3 PUFA to the total FA were higher
in NEFA than in AT, whereas the contribution of MUFA was lower
in NEFA than in AT (Fig. 1). The proportions of n-6 PUFA were
comparable between NEFA and AT. The ﬁve most prevalent FA
(oleic, palmitic, linoleic, palmitoleic and stearic acid) were con-
sistent in both pools and accounted for 90·8% of the FA in AT and
85·6% of the FA in NEFA (Table 3). DHA, EPA and arachidonic
acid accounted for 4% of NEFA, but only 0·7% of FA in AT.
Agreement and relationship between fatty acids in adipose
tissue and NEFA
The concordance between AT and NEFA for twenty-eight FA at
three time points over the 12-month period is shown in Table 4.
Concordance at all three time points was poor (<0·6), but it was
highest for linoleic acid (18 : 2n-6; 0·34–0·53 depending upon
the time point).
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Concordance for total SFA, MUFA and n-3 PUFA was poor
(<0·1) (Table 4). For total n-6 PUFA, concordance was 0·28–
0·43 over the course of the 12-month period.
The relationship between AT and NEFA assessed by corre-
lation coefﬁcient was also poor (<0·59) (Table 4). The rela-
tionship was strongest between n-6 PUFA, but in contrast to the
agreement SFA and MUFA were moderately correlated
(approximately 0·2) at 0 and 6 months (Table 4).
Can NEFA values predict adipose tissue fatty acid values at
baseline?
To test whether NEFA may be used as a surrogate for AT FA
proﬁles, prediction models were ﬁtted to baseline data from the
training set (70 % of the study population) and then used to
predict FA levels in AT in the validation set (the remaining 30 %
of the study population). These predicted values were com-
pared with observed values in the validation set (Fig. 2(a) and
(b)). We examined n-6 PUFA, which showed moderate con-
cordance between AT and NEFA, and SFA, which showed poor
concordance (Table 3).
There was an association for n-6 PUFA between NEFA and
AT in the training set (P< 0·0001), although with sex included in
the model only 32 % of the variance in the data was explained.
Although this model predicted AT n-6 PUFA values with a
moderate level of error (MAPE of 11 %, the predicted values
performed poorly at discriminating high and low observed
levels of AT n-6 PUFA (Fig. 2(a)). Predicted values correctly
classiﬁed 25 % of values of n-6 PUFA into low, medium or high
categories, but misclassiﬁed 75 %.
There was a weak association for SFA between NEFA and
AT in the training set (P= 0·04), which explained only 7 %
Table 1. Characteristics of participants at the three study time points for which there were data available for adipose tissue (AT) and NEFA comparison
(Mean values and standard deviations)
0 months 6 months 12 months
Mean SD Mean SD Mean SD Difference (P)*
n (AT samples) 202 160 156
Sex (male %) 49 50 52
Age (years) 48·4 16·1 50·2 15·4 50·7 15·2
BMI (kg/m2) 25·6 3·88 25·8 3·85 25·7 3·92 0·30
Body fat (%) 21·9 8·55 22·2 7·92 21·8 8·10 0·64
Dietary fat (%E) 34·1 5·76 34·1 6·17 34·1 5·37 0·79
Dietary SFA (%E) 12·8 3·12 13·1 3·30 12·7 2·83 0·18
Dietary MUFA (%E) 11·4 2·24 11·32 2·45 11·4 2·22 0·99
Dietary n-3 PUFA (%E)† 0·75 0·25 0·76 0·23 0·76 0·24 0·60
Dietary n-6 PUFA (%E) 5·20 1·76 4·90 1·35 5·15 1·65 0·17
% E, percentage of total energy intake.
* The P value of the difference in means between the three time points assessed by repeated-measures ANOVA.
† Excluding n-3 PUFA provided as the intervention supplements.
Table 2. Characteristics of participants at baseline in the training set and validation set
(Mean values and standard deviations)
Training set Validation set
Mean SD Mean SD Difference (P)*
n 143 61
% population 70 30
Sex (male %) 50 44 0·43
Age (years) 48·4 16·5 48·5 15·6 0·98
BMI (kg/m2) 25·4 3·94 26·0 3·66 0·31
Body fat (%) 21·3 8·55 23·2 8·34 0·15
Dietary fat (%E) 34·0 5·48 34·2 6·43 0·85
Dietary SFA (%E) 12·8 3·16 12·9 3·12 0·80
Dietary MUFA (%E) 11·4 2·07 11·3 2·25 0·74
Dietary n-6 PUFA (%E) 5·09 1·71 5·41 1·84 0·24
Dietary n-3 PUFA (%E)† 0·75 0·23 0·74 0·31 0·70
SFA in AT 31·0 3·76 30·4 2·75 0·27
MUFA in AT 52·7 3·44 52·7 3·08 0·93
n-6 PUFA in AT 13·7 2·53 13·8 2·73 0·15
n-3 PUFA in AT 1·64 0·32 1·61 0·28 0·52
SFA in NEFA 36·3 3·11 37·1 4·26 0·15
MUFA in NEFA 42·5 5·36 42·4 4·41 0·91
n-6 PUFA in NEFA 13·6 2·67 13·8 1·94 0·64
n-3 PUFA in NEFA 4·01 1·77 3·61 1·18 0·11
% E, percentage of total energy intake; AT, adipose tissue.
* Differences (P) between the training and validation set were assessed by t test.
† Excluding n-3 PUFA provided as the intervention supplements.
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of the variance in the data (including age, sex and BMI in
the model). Consequently, although the values for AT SFA
predicted from the model in the validation set had moderately
low error compared with the observed AT SFA (MAPE of 8 %),
they were poor at discriminating high and low observed
levels of SFA (Fig. 2(b)). The predicted values correctly classi-
ﬁed 33 % of values into low, medium or high categories
of AT SFA according to the observed values, but misclassi-
ﬁed 67 %.
Can NEFA predict adipose tissue EPA and DHA after an
intervention to increase intake?
There was a strong association between AT and NEFA EPA in
the training set at baseline (P= 0·001), accounting for age, sex
and BMI. However, there was no association following the
intervention (P= 0·8). Similarly, there was an association
between AT and NEFA DHA at baseline in the training set
(P= 0·014), but not following the intervention (P= 0·3). Con-
sequently, these models could not be used to predict
proportions of EPA and DHA in AT in the validation set fol-
lowing the intervention.
Discussion
This study shows that despite the majority of plasma NEFA
being derived from AT lipolysis, there was poor agreement
between FA in AT and NEFA, particularly for SFA. Furthermore,
NEFA cannot be used as a minimally invasive surrogate marker
to reﬂect changes in AT in response to a 12-month intervention
to increase EPA and DHA consumption.
Although we, and others(1,5,12), have shown moderate to good
correlations between FA in AT and NEFA, the agreement
described by the concordance in this study was generally very
poor. Previous studies tested the relationship between NEFA and
AT by correlation coefﬁcient, which indicated a strong linear
relationship between the two values, whereas in our study, as we
were interested in whether NEFA values may act as a surrogate
marker, we have tested agreement by concordance. In line with
the ﬁndings in this study, a previous study indicated strong
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Fig. 1. Comparison of fatty acids by class in adipose tissue (AT) and NEFA at baseline: (a) SFA, (b) MUFA, (c) n-6 PUFA, (d) n-3 PUFA. Data are median, 25 and 75th
percentile and range for proportion of total fatty acids contributed by each class.
Table 3. Proportion of total of the five most abundant fatty acids (FA) in both adipose tissue (AT) and NEFA fractions and the cumulative proportion of total
of these FA at baseline
(Mean values and standard deviations)
AT (% of total FA) NEFA (% of total FA)
Mean SD Mean SD
Oleic acid (18 : 1n-9) 45·8 2·63 35·5 4·36
Palmitic acid (16 : 0) 22·5 2·48 22·7 2·28
Linoleic acid (18 : 2n-6) 13·4 2·72 12·6 2·49
Palmitoleic acid (16 : 1n-7) 5·18 1·49 3·15 1·21
Stearic acid (18 : 0) 3·94 1·09 11·6 2·40
Cumulative total 90·7 1·02 85·7 3·35
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the line of agreement (the identity line), particularly for n-3
PUFA and SFA (16 : 0 and 18 : 0)(12). In our study, the poor
concordance was reﬂected by a poor ability to predict high and
low AT FA values, particularly for SFA (Fig. 2(b)).
The agreement between AT and NEFA was markedly better
for n-6 PUFA than any other FA class, as has been found
previously in a cohort of patients with myocardial infarction and
age-matched controls(12) and in a cohort of women who were
predominantly obese(5). FA are selectively mobilised according
to structure(17); generally, mobilisation is greater for essential
FA(18), greater with the degree of saturation, but lower with
chain length for any degree of saturation(19). This may explain
Table 4. Concordance correlation coefficients between percentage of total fatty acids in adipose tissue and NEFA for each participant at baseline,
6 and 12 months*














10 : 0 –0·01 –0·02 0·08 0·06 0·02 0·14
12 : 0 –0·01 –0·15 0·01 0·04 –0·09 –0·09
13 : 0 –0·09 –0·07 –0·05 –0·04 –0·0 –0·07
14 : 0 0·02 0·13 0·05 0·25 0 0·10
14 : 1n-9 0·06 0·26 0·01 0·15 0·41 0·59
15 : 0 0·14 0·22 0·36 0·42 –0·01 0·15
15 : 1 0·01 0·06 –0·08 –0·02 –0·05 –0·01
16 : 0 0·21 0·31 0·28 0·35 0·06 0·20
16 : 1n-7 0·16 0·29 0·26 0·55 0·17 0·45
17 : 0 0·01 0·12 0·01 0·24 –0·03 –0·06
17 : 1n-8 –0·15 –0·30 –0·03 0·01 0·33 0·32
18 : 0 0·01 0·20 0·01 0·28 –0·01 –0·06
18 : 1n-9 0·01 0·16 0·02 0·22 –0·02 –0·08
18 : 2n-6 0·42 0·43 0·53 0·57 0·34 0·47
18 : 3n-6 0·02 0·14 0·09 0·23 –0·01 0·00
18 : 3n-3 0·21 0·20 0·39 0·51 0·22 0·35
20 : 0 0·11 0·10 0 –0·04 0·06 0·27
20 : 1n-9 0 0·07 0·06 0·29 0·34 0·33
20 : 2n-6 0·03 0·25 0·18 0·17 0·02 0·04
20 : 3n-3 –0·04 –0·11 0·05 0·16 0 0·03
20 : 3n-6 0·01 0·34 0 0·03 0·08 0·26
20 : 4n-6 0 0·04 0·01 0·07 –0·01 –0·08
20 : 5n-3 0·06 0·27 0·01 0·13 0·03 0·21
22 : 0 0·03 –0·01 –0·01 –0·08 0·05 0·02
22 : 4n-6 0·02 0·06 0·03 0·03 0·08 0·18
22 : 5n-3 0·01 0·04 –0·04 –0·06 –0·01 –0·01
22 : 5n-6 0·01 0·02 0 0·03 0·02 0·01
22 : 6n-3 0·02 0·24 0·01 0·16 0·01 0·21
SFA 0·07 0·22 0·05 0·28 –0·06 –0·09
MUFA 0·03 0·17 0·03 0·24 –0·01 0·01
n-6 PUFA 0·28 0·51 0·43 0·59 0·34 0·47
n-3 PUFA 0·01 0·16 0·01 0·17 0·02 0·16
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Fig. 2. Predicted adipose tissue (AT) n-6 PUFA and SFA compared with observed AT values at baseline. Predicted AT n-6 PUFA values (a) and SFA values (b) were
generated from equations of comparison of NEFA n-6 PUFA and SFA with AT and including age, sex and BMI in the training set. These predicted values for AT n-6
PUFA and SFA were compared with the observed values in the validation set. FA, fatty acids.
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the greater prevalence of EPA, DHA and arachidonic acid seen
in NEFA compared with AT. It has also been suggested that
other factors such as physical activity(6,20), BMI(5) and insulin
sensitivity(21) contribute to selective mobilisation of FA. In
addition, differences between AT FA proﬁle and NEFA are also
contributed to by de novo lipogenesis in particular contributions
of SFA, preferential postprandial uptake of FA(4) and utilisation
of n-6 and n-3 PUFA such as arachidonic acid, EPA and DHA
for synthesis of eicosanoids and other bioactive compounds(22).
We explored further whether NEFA may be used as mini-
mally invasive markers of changes in AT FA composition in
response to changes in n-3 PUFA intake. In this study, we
demonstrated that there was poor concordance between EPA
(20 : 5n-3) and DHA (22 : 6n-3) before and in response to an
intervention to increase EPA and DHA intake. There was an
association between AT and NEFA for both EPA and DHA
before, but not after, the intervention. This indicates that the
supplementation resulted in EPA and DHA changes in one pool
that were not mirrored in the other pool. Because of the lack of
association, we were unable to create prediction equations to
test the accuracy of NEFA as a biomarker of AT n-3 PUFA, as we
had done for n-6 PUFA and SFA. However, it is clear from the
very poor concordance and the lack of association that NEFA
EPA and DHA would not be able to predict AT EPA and DHA
with any accuracy. Although EPA and DHA in both AT and
NEFA are increased in accordance with an increase in
intake(13,23,24), there is only a moderate correlation between
change in AT and NEFA EPA+DHA (Spearman’s correlation=
0·27), and we have demonstrated here that changes in AT
cannot be predicted from changes in NEFA. We have suggested
previously that blood markers, particularly mononuclear cells,
may be better at discriminating long-term changes in EPA and
DHA intake than AT(13).
AT FA proﬁle has important implications for biological
function; in particular, proportions of arachidonic acid, EPA and
DHA affect the inﬂammatory proﬁle(22,25). Although there are
strong correlations between AT FA in subcutaneous and visceral
depots, differences in proportions of speciﬁc FA between the
depots have been found; for example, FA of longer chain length
(>22 C) are more predominant in subcutaneous AT and highly
unsaturated FA in visceral depots(5). In addition, there are dif-
ferences in FA proﬁle and metabolism between subcutaneous
AT depots of different origins(26,27). This may contribute to the
lack of concordance found between AT and NEFA in this study,
and it would limit the utility of NEFA as a surrogate for AT FA, as
proﬁle differences important for AT biological function would
not be reﬂected in the overall NEFA proﬁle.
This study has several strengths, as it assessed the agreement
of a number of FA (twenty-eight) between AT and NEFA at
repeated time points over a 12-month period. We measured
forty FA, but because of low amounts in one or other of the
pools data for twelve FA could not be used. This study was
conducted in male and female participants of a wide age and
BMI range, representative of the population, and in a com-
paratively large number of individuals. We also assessed the
utility of NEFA as a surrogate for changes in AT FA in response
to a 12-month intervention to increase EPA and DHA con-
sumption. A limitation of this study is that AT was only sampled
from the abdominal subcutaneous depot. There are differences
in FA proﬁle and metabolism of FA between subcutaneous and
visceral depots, as well as between subcutaneous depots at
different locations(26,28), which may explain the poor agreement
between NEFA and AT FA found in the current study. It is
possible the NEFA better reﬂect the FA proﬁle of visceral AT,
and as this depot is even more invasive to sample from it would
be useful to know whether NEFA are a good reﬂection of this
more biologically active depot(28).
In conclusion, despite moderate correlation between AT and
NEFA FA proﬁles, NEFA are not a suitable surrogate for AT FA.
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